The U.S. Food and Drug Administration ... a novel gene therapy developed by Ultragenyx Pharmaceutical Inc. designed to combat Sanfilippo syndrome type A, a devastating rare neurological disorder. Sanfilippo syndrome type A, also known as mucopolysaccharidosis type III A (MPS IIIA), is a progressive and fatal inherited metabolic disease. Children born with this condition lack the necessary enzymes to break down complex sugars within their cells... The U.S. Food and Drug Administration (FDA) has granted approval for Fayuvi, a novel gene therapy developed by Ultragenyx Pharmaceutical Inc. designed to combat Sanfilippo syndrome type A, a devastating rare neurological disorder. Sanfilippo syndrome type A, also known as mucopolysaccharidosis type III A (MPS IIIA), is a progressive and fatal inherited metabolic disease. Children born with this condition lack the necessary enzymes to break down complex sugars within their cells. FDA approved Fayuvi gene therapy for Sanfilippo syndrome type A in children two and older, showing slowed cognitive decline despite high cost concerns. The treatment employs a viral vector engineered to deliver a functional copy of the gene responsible for producing the deficient enzyme directly into the patient's cells. The therapeutic objective is to restore, at least partially, the body's ability to metabolize cellular waste, thereby aiming to slow or halt the disease's relentless progression. This metabolic breakdown leads to a relentless accumulation of cellular debris, resulting in severe neurological damage. The consequences for affected children are stark: progressive cognitive decline, loss of acquired speech, motor impairments, and typically, a lifespan that does not extend beyond adolescence. Fayuvi represents a significant advancement, utilizing a sophisticated gene therapy approach.

The FDA approved Genglycos (pariglasgene brecaparvovec-opnr) to reduce daily cornstarch intake in patients aged 8 years and older with glycogen storage disease type Ia. Known as Von Gierke disease, GSDIa is a rare metabolic disorder caused by a mutation in the G6PC gene. This genetic variation leads to a deficiency in glucose-6-phosphatase (G6Pase), an enzyme needed to release glucose into the bloodstream. Without this enzyme, the body cannot properly maintain blood glucose levels, causing severe hypoglycemia and other serious metabolic complications · Pariglasgene brecaparvovec is an adeno-associated virus (AAV) serotype 8 based gene therapy that delivers a functional copy of the G6PC gene into liver cells, enabling the production of normally functioning G6Pase. Ultragenyx stated that as part of its postmarketing commitments to the FDA, the Company will provide 2 years of clinical data from open-label commercial treatment of 50 patients and 20 control patients through its existing GSDIa Disease Monitoring Program. ... Ultragenyx announces US FDA approval of Genglycos™ gene therapy, the first-ever FDA-approved treatment designed to treat the underlying cause of glycogen storage disease type Ia (GSDIa). “The reduced reliance on cornstarch, experienced by patients in our clinical studies, demonstrates this gene therapy’s ability to establish the normal breakdown of glycogen to produce glucose during fasting or episodes of metabolic stress. This ability to regulate glucose has alleviated the disease burden and has the potential to mitigate the risk of severe or life-threatening hypoglycemia for these patients.” Close more info about First Gene Therapy Approved for Glycogen Storage Disease Type la